Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates. 2023

Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.

The availability of new β-lactam/β-lactamase inhibitors ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam have redefined contemporary treatment of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) infections. We aimed to characterize and contrast the in vitro activity of these agents against genetically diverse KPC-Kp clinical isolates. We analysed genomes of 104 non-consecutive KPC-Kp isolates and compared the in vitro antibiotic activity by KPC subtype and ompK36 genotype. MICs were determined in triplicate by CLSI methods. Twenty representative isolates were selected for time-kill analyses against physiological steady-state and trough concentrations, as well as 4× MIC for each agent. Fifty-eight percent and 42% of isolates harboured KPC-2 and KPC-3, respectively. OmpK36 mutations were more common among KPC-2- compared with KPC-3-producing Kp (P < 0.0001); mutations were classified as IS5 insertion, glycine-aspartic acid insertion at position 134 (GD duplication) and other mutations. Compared to isolates with WT ompK36, ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam MICs were elevated for isolates with IS5 by 2-, 4- and 16-fold, respectively (P < 0.05 for each). Against isolates with GD duplication, imipenem/relebactam and meropenem/vaborbactam MICs were increased, but ceftazidime/avibactam MICs were not. In time-kill studies, ceftazidime/avibactam-mediated killing correlated with ceftazidime/avibactam MICs, and did not vary across ompK36 genotypes. Imipenem/relebactam was not bactericidal against any isolate at trough concentrations. At steady-state imipenem/relebactam concentrations, regrowth occurred more commonly for isolates with IS5 mutations. Log-kills were lower in the presence of meropenem/vaborbactam for isolates with GD duplication compared with IS5 mutations. Our investigation identified key genotypes that attenuate, to varying degrees, the in vitro activity for each of the new β-lactam/β-lactamase inhibitors. Additional studies are needed to translate the importance of these observations into clinical practice.

UI MeSH Term Description Entries

Related Publications

Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
May 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
November 2022, Antibiotics (Basel, Switzerland),
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
April 2022, Infection,
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
May 2024, Antibiotics (Basel, Switzerland),
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
December 2022, Infection,
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
May 2019, The Journal of antimicrobial chemotherapy,
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
September 2023, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
January 2023, Antibiotics (Basel, Switzerland),
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
October 2020, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians,
Tara M Rogers, and Ellen G Kline, and Marissa P Griffith, and Chelsea E Jones, and Abigail M Rubio, and Kevin M Squires, and Ryan K Shields
August 2023, JAC-antimicrobial resistance,
Copied contents to your clipboard!